also demonstrated that the frequent loss of the CDKN2A could trigger the susceptibility to IFN-γ resistance via JAK2 gene deletion in melanoma (66), which was in line with our conclusion that high expression of CDKN2A potentially benefited from immunotherapy. This evidence concerns the gene JAK2 and melanoma.